Skip to main content
MANNKIND CORP logo

MANNKIND CORP — Investor Relations & Filings

Ticker · MNKD ISIN · US56400P7069 LEI · 213800GFBCNY1ZFST722 US Manufacturing
Open in API
Filings indexed 1,205 across all filing types
Latest filing 2012-10-22 Legal Proceedings Report
Country US United States of America
Listing US MNKD

About MANNKIND CORP

https://mannkindcorp.com/

MannKind Corporation is a biopharmaceutical company focused on the development and commercialization of therapeutic products and devices. The company specializes in inhaled therapies for patients with cardiometabolic and orphan lung diseases. Its portfolio includes Afrezza®, an inhaled insulin for diabetes, and Tyvaso DPI®, a dry powder inhaler for pulmonary hypertension developed in collaboration with United Therapeutics. Through its acquisition of scPharmaceuticals, MannKind also markets FUROSCIX®, a subcutaneous treatment for edema in adults with chronic heart failure. The company's pipeline is focused on expanding indications for its existing products, including a pediatric application for Afrezza.

Recent filings

Filing Released Lang Actions
FORM 8-K/A
Legal Proceedings Report Classification · 95% confidence The document is a Form 8-K/A filed with the SEC, which is an amendment to a previously filed Form 8-K. It primarily corrects dates related to court approval hearings for settlements of securities and derivative litigation involving the company. The content focuses on legal proceedings and settlement notices rather than financial results, management changes, or other report types. It includes references to court orders, settlement notices, and stipulations of settlement, which are typical of legal proceedings updates. There is no substantive financial data or management discussion, nor is it a proxy, earnings release, or capital update. Therefore, the document fits best under the category of Legal Proceedings Report (LTR).
2012-10-22 English
FORM 8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content details a material definitive agreement involving a stock and warrant purchase agreement, amendments to a promissory note, and an underwriting agreement for a public offering of common stock and warrants. It includes descriptions of the agreements, terms of the offering, and related press releases. There are no financial statements or comprehensive financial data presented, nor is this an annual or quarterly report. The document is primarily an announcement of financing activities and agreements related to capital raising. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length is substantial (over 12,000 characters), indicating it is not a brief announcement or a simple press release, but a detailed filing about financing transactions.
2012-10-19 English
FINAL PROSPECTUS SUPPLEMENT
Capital/Financing Update Classification · 100% confidence The document is a 'Final Prospectus Supplement' filed pursuant to Rule 424(b)(5) and relates to an offering of common stock and warrants. It includes detailed information about the securities being offered, underwriting, risk factors, use of proceeds, and legal matters. This type of document is a prospectus supplement related to a capital raising event, specifically a public offering of shares and warrants. It is not a financial report, earnings release, or management discussion. It is a detailed disclosure document for investors about a financing transaction. Therefore, it fits the category of Capital/Financing Update (CAP). The document length and content confirm it is not a brief announcement or a regulatory filing fallback. Confidence is high given the explicit nature of the document as a prospectus supplement for a securities offering.
2012-10-19 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content includes preliminary financial results, updates on loan arrangements, and business updates related to clinical trials and regulatory interactions. It does not contain full audited financial statements or comprehensive financial performance data typical of an Annual Report (10-K) or Interim Report (IR). It also does not focus on management changes, earnings release highlights, or legal proceedings. The document primarily provides a financial condition update and other material events, consistent with the purpose of an 8-K filing. Therefore, the best classification is Regulatory Filings (RNS), which is the fallback category for miscellaneous SEC filings like Form 8-K that do not fit other specific categories.
2012-10-17 English
PRELIMINARY PROSPECTUS SUPPLEMENT
Capital/Financing Update Classification · 95% confidence The document is a Preliminary Prospectus Supplement filed pursuant to Rule 424(b)(5) with the SEC, describing an offering of common stock and warrants by MannKind Corporation. It includes detailed information about the securities being offered, underwriting, use of proceeds, risk factors, and concurrent private placement. This type of document is a capital raising filing related to financing activities, specifically a prospectus supplement for a securities offering. It is not an annual or quarterly report, earnings release, or any other type of report. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains detailed offering terms, consistent with a financing update rather than a brief announcement or regulatory filing. Confidence is high due to the clear identification of the document as a prospectus supplement and the detailed offering information.
2012-10-17 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce significant events. The content describes the completion of patient recruitment for Phase 3 clinical studies and references an attached press release. There are no financial statements, earnings data, or detailed financial analysis present. The document is primarily an announcement of a corporate event rather than a financial report or management discussion. It does not fit into categories like Annual Report, Earnings Release, or Management Reports. It is also not a regulatory certification or insider transaction. Given the nature of the content and the form type, the best fitting category is Regulatory Filings (RNS), which serves as a fallback for miscellaneous filings that do not fit other specific categories.
2012-10-05 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.